Krystal Biotech Inc Cash Flow Conversion Efficiency
Krystal Biotech Inc cash flow conversion efficiency. Based on the latest financial reports, Krystal Biotech Inc (KRYS) has a cash flow conversion efficiency ratio of 0.055x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($74.79 Million) by net assets ($1.36 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Krystal Biotech Inc (2016–2025)
Cash flow conversion efficiency of Krystal Biotech Inc from 2016 to 2025. This chart illustrates how Krystal Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View KRYS stock price for real-time trading data and today's change.
Krystal Biotech Inc Cash Flow Conversion Ratio Explained
Krystal Biotech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Krystal Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Krystal Biotech Inc ranked by their cash flow conversion efficiency. Also see KRYS company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dick’s Sporting Goods Inc
NYSE:DKS
|
0.062x |
|
Vaxcyte Inc
NASDAQ:PCVX
|
-0.186x |
|
The Siam Cement Public Company Limited
BK:SCC
|
0.012x |
|
Central Pattana Public Company Limited
BK:CPN
|
0.078x |
|
Globus Medical
NYSE:GMED
|
0.086x |
|
Sirius XM Holding Inc
NASDAQ:SIRI
|
0.023x |
|
Keyera Corp.
TO:KEY
|
0.128x |
|
Crinetics Pharmaceuticals Inc
NASDAQ:CRNX
|
-0.079x |
Annual Cash Flow Conversion Efficiency for Krystal Biotech Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Krystal Biotech Inc from 2016 to 2025. Review cash generation quality of Krystal Biotech Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.22 Billion | $200.87 Million | 0.165x | +26.29% |
| 2024-12-31 | $946.38 Million | $123.42 Million | 0.130x | +214.35% |
| 2023-12-31 | $778.64 Million | $-88.80 Million | -0.114x | +40.78% |
| 2022-12-31 | $522.23 Million | $-100.57 Million | -0.193x | -138.45% |
| 2021-12-31 | $593.58 Million | $-47.94 Million | -0.081x | +9.56% |
| 2020-12-31 | $292.08 Million | $-26.08 Million | -0.089x | +3.17% |
| 2019-12-31 | $202.91 Million | $-18.71 Million | -0.092x | -10.55% |
| 2018-12-31 | $113.23 Million | $-9.45 Million | -0.083x | -6.09% |
| 2017-12-31 | $49.47 Million | $-3.89 Million | -0.079x | +98.27% |
| 2016-12-31 | $289.00K | $-1.31 Million | -4.536x | -- |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystro… Read more